featured
Atezolizumab Plus Bevacizumab and Chemotherapy for Metastatic, Persistent, or Recurrent Cervical Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial
Lancet 2023 Dec 01;[EPub Ahead of Print], A Oaknin, L Gladieff, J Martínez-García, G Villacampa, M Takekuma, U De Giorgi, K Lindemann, L Woelber, N Colombo, L Duska, A Leary, A Godoy-Ortiz, S Nishio, A Angelergues, MJ Rubio, L Fariñas-Madrid, S Yamaguchi, D Lorusso, I Ray-Coquard, L Manso, F Joly, J Alarcón, P Follana, I Romero, C Lebreton, JA Pérez-Fidalgo, M Yunokawa, H Dahlstrand, V D'Hondt, LM RandallFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.